anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention discloses a traditional Chinese medicine formula for treating pneumonia of goat. The traditional Chinese medicine formula is composed of the following components by weight: 25 to 40 grams of mulberry leaf, 25 to 40 grams of bitter apricot kernel, 20 to 30 grams of adenophora stricta, and 15 to 25 grams of fritillaria cirrhosa. The preparation method comprises the following steps: putting the components mentioned above into a pot, adding 500 to 800 mL of drinking water, decocting the raw materials for 15 to 20 minutes, cooling, and removing dregs. The traditional Chinese medicine formula has the functions of clearing heat, removing toxin, clearing the lung heat, moistening dryness, dispelling wind-heat, killing bacteria, and eliminating inflammation, and can effectively treat goat's pneumonia caused by wind cold. The pneumonia of goat can be cured after 5 to 7 doses. The effective rate is 92 to 95%.
C-11 ER176 is an investigational radiopharmaceutical that will be produced under cGMP in the Mayo Clinic Cyclotron Facility. The imaging agent (C-11 ER176) will be administered on an outpatient basis. It will be administered at a single time IV prior to the PET imaging.
The study duration for an individual patient will include a screening period for inclusion of up to 21 days. The treatment period may continue until disease progression, unacceptable adverse reaction, or other reason for discontinuation. After study treatment discontinuation an end of treatment (EOT) visit will be done at approximately 30 days after last study treatment component administration to assess safety. If the last ADA sample is positive or inconclusive, additional ADA will be sampled 3 months later. No further ADA will be sampled, even if this 3-month sample is positive. Patients who discontinue treatment for reasons other than progression of disease will be followed every month until progression or initiation of subsequent therapy, for a maximum of one year, whichever comes first.
Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) has been reported in patients taking NSAIDs such as COXANTO. Some of these events have been fatal or life-threatening. DRESS typically, although not exclusively, presents with fever, rash, lymphadenopathy, and/or facial swelling. Other clinical manifestations may include hepatitis, nephritis, hematological abnormalities, myocarditis, or myositis. Sometimes symptoms of DRESS may resemble an acute viral infection. Eosinophilia is often present. Because this disorder is variable in its presentation, other organ systems not noted here may be involved. It is important to note that early manifestations of hypersensitivity, such as fever or lymphadenopathy, may be present even though rash is not evident. If such signs or symptoms are present, discontinue COXANTO and evaluate the patient immediately.
<P>PROBLEM TO BE SOLVED: To provide compounds used for chemical peeling.  <P>SOLUTION: The chemical peeling accelerates natural removal of stratum corneum in very deep level and induces necrosis and inflammation of epidermis, stratum papilare of dermis or stratum reticulare of dermis. Therefore, the prescription accomplishes chemical peeling in one aspect and minimizes damage risk of patients of skin therapy in the other aspect. More preferably, the present invention relates to a composition for chemical peeling containing at least one stratum corneum dissolving agent and dimethyl isosorbide. The composition may further contain dimethylsulfone.  <P>COPYRIGHT: (C)2009,JPO&INPIT
Mainstream and alternative nutrition doctrines have crucially shaped our understanding of the vital aspects of and forces in human nutrition. Drawing upon a diverse array of sources, this article delves into cultural, social, and scientific conceptions of vital nutrition and how they evolved in relation to the Finnish obesity discourse from the 1950s to the 1970s. The Association to Combat Obesity (ACO), which brought together nutrition scientists, food faddists and laypeople, was the driving force of these debates. In the context of this article, food was perceived to influence the vitality of individuals and nations through its effect on body weight. Obese bodies seemed to conflict with both utopian visions of bodily transcendence and the ideals of wellbeing in modern health sciences. This work highlights the ideological continuities between interwar and postwar nutrition debates as well as the persistent tensions between scientific advancements and alternative nutrition philosophies. They have molded the conceptions of vitality and attitudes towards obesity. Concludingly, we suggest that the social responses to obesity have been influenced by the condition's perceived adverse relationship to vitality, in which fat has acted as a persistent reminder of corporeality, death, and decay.
The aim of this study is to investigate a new, non invasive treatment for epilepsy that may be useful as an adjunctive therapy for people whose seizures are poorly controlled with anti epileptic drugs. Light therapy is a well established treatment for some forms of depression. From the cellular level to epidemiological studies, there are numerous strands of evidence in the scientific literature that indicate that light therapy could be also an effective treatment for some people with epilepsy.

The proposed study is a randomised placebo controlled trial of light therapy. One hundred people with medically refractory epilepsy will be recruited. Participants will be randomised to receive either therapeutic or placebo doses of light therapy from an identical device for 30 minutes a day during the treatment phase of the study. The statistical power of this study design is \>90% to detect a 25% reduction in seizure frequency during the treatment phase. Although this therapeutic approach is more likely to be palliative than curative, it represents a non invasive and relatively inexpensive add-on treatment option for a sub group of patients who may have reached the end of the road in other medical and surgical treatment options.
PROBLEM TO BE SOLVED: To suppress the damage to the hair, to improve the finish and to maintain a well shaped state by treating the hair with strongly electrolytic acidic water during the time of both treatments at the time of applying the cold permanent wave to the hair by successively treating the hair with plural treating agents consisting of a reducing agent for cold permanent wave and an oxidizing agent. SOLUTION: The hair is first treated by the treating agent consisting of the reducing agent for treating agent, i.e., the reducing agent for reducingly cutting the S-S bond of the hair protein. Next, the hair is treated by the treating agent likewise consisting of the oxidizing agent, i.e., the oxidizing agent for oxidatively rebonding the S-S bond. The hair may be previously treated with the strongly electrolytic alkaline water. The strongly electrolytic acidic water signifies water of a pH below 2.7 and oxidation reduction potential above +1000 mV. On the other hand, the strongly eletrolytic alkaline water signifies the water of the oxidation reduction potential below -800 mV.
PURPOSE:To obtain a safe antimicrobial agent, containing plural N-long-chain acylamino acid salts in which different metals having antimicrobial properties are bound, having a wide antimicrobial spectrum with high antimicrobial action without eliminating the bound antimicrobial metals. CONSTITUTION:An antimicrobial agent containing two or more N-long chain aclylamino acid salts in which metals having different antimicrobial properties, preferably silver or copper as an essential metal and at least one, especially two or more metals selected from other metals (silver, copper, lead, zinc, tin, bismuth, etc.) are bound therein. Stearoyl, lauroyl, myristoyl and palmitoyl groups are cited as the acyl group in the N-long chain acylamino acid salts. A monoaminodicarboxylic acid is preferred as the amino acid part. The aforementioned agent is blended with other ingredients to prepare antimicrobial resin compositions, paper having antimicrobial properties, antimicrobial synthetic fibers, antimicrobial coatings, local antimicrobial agents, cosmetics, etc.
Removal of colorectal adenomas prevents occurrence of cancers. It is recognized that colonoscopy can miss colorectal adenomas and early cancers. Proximal colon polyp detection rate is lower compared to distal colon detection rates. This may be partially due to the higher prevalence of flat polyps and sessile serrated adenomas (SSAs) which are harder to visualize. There is a need to further improve performance of colonoscopy. A second evaluation of the right colon within the same procedure may yield an additional detection rate of 5-10%, however retro-flexion has not proven to be superior to a second forward viewing examination. The use of chromo-endoscopy has been shown to improve detection of flat adenomas. Narrow band imaging was introduced in year 2006. It is similar to chromo-endoscopy in that it provides more mucosal details. This enables endoscopists to accurately describe the pit pattern of adenomas. NBI has been used as a substitute to chromo-endoscopy. In pooled analysis, NBI is comparable to chromo-endoscopy in their sensitivity and specificity in the diagnosis of malignant colorectal adenomas. Unfortunately, the use of NBI has not been shown to conclusively improve rate of colorectal adenoma detection. Two of 3 randomized trials that compared WLE to NBI showed a higher adenoma detection rate with the use of NBI. In a study by Rex et al., the rate was however similar with either modality. In a pooled analysis, NBI was only marginally better than WLE.

The effective use of NBI depends on the quality of bowel preparation and the experience of endoscopist. In the presence of fecal matters, NBI tends to be dark and detection of small adenomas becomes difficult. The prototype bright NBI coupled with high definition resolution is likely to overcome this drawback of original NBI.
In a few cases, a clinical syndrome closely resembling adrenal insufficiency and characterized by weakness, severe fatigue, anorexia, weight loss, nausea and vomiting, and melanoderma has developed after prolonged busulfan therapy. The symptoms have sometimes been reversible when busulfan was withdrawn. Adrenal responsiveness to exogenously administered ACTH has usually been normal. However, pituitary function testing with metyrapone revealed a blunted urinary 17-hydroxycorticosteroid excretion in 2 patients. Following the discontinuation of busulfan (which was associated with clinical improvement), rechallenge with metyrapone revealed normal pituitary-adrenal function.

Hyperuricemia and/or hyperuricosuria are not uncommon in patients with chronic myelogenous leukemia. Additional rapid destruction of granulocytes may accompany the initiation of chemotherapy and increase the urate pool. Adverse effects can be minimized by increased hydration, urine alkalinization, and the prophylactic administration of a xanthine oxidase inhibitor such as allopurinol.
Patients receive selumetinib PO BID on day -7 of course 1 and then on days 1-28 (one dose on day 1 only). Patients also receive cyclosporine PO BID on day -3 of course 1 and then on days 1-28 (one dose on day 1 only). Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Despite considerable scientific effort in the last two decades to develop treatment for cocaine dependent individuals, no medication has proven to be effective for treating cocaine dependence. Cocaine's rewarding effects are primarily a result of altering nerve pathways involving dopamine, a naturally-occurring chemical in the brain. Past research has focused on developing medications that either block dopamine or inhibit its release. However, these medications have not proven effective in treating cocaine dependence. This study will evaluate a new strategy of treating cocaine dependence by altering dopamine's functional expression. Dopamine-associated expression may be mediated through inhibition of gamma-aminobutyric acid (GABA), another brain chemical. Topiramate is a GABA inhibitor that has proven effective in treating alcohol dependent individuals. The purpose of this study is to determine the efficacy of topiramate in treating cocaine dependent individuals.

Participants will be randomly assigned to receive either 300 mg per day of topiramate or placebo. In addition, participants will receive weekly cognitive behavioral therapy for 12 weeks. Follow-up visits will occur at 2 weeks and 1, 2, and 3 months following completion of treatment, and will include evaluations of cocaine use and psychosocial functioning.
Methods and compositions are provided for inducing phagocytosis of a target cell, treating an individual having cancer, treating an individual having an intracellular pathogen infection (e.g., a chronic infection), and/or reducing the number of inflicted cells (e.g., cancer cells, cells infected with an intracellular pathogen, etc.) in an individual. Methods and compositions are also provided for predicting whether an individual is resistant (or susceptible) to treatment with an anti-CD47/SIRPA agent. In some cases, the subject methods and compositions include an anti-MHC Class I/LILRB1 agent. In some cases, the subject methods and compositions include an anti-MHC Class I/LILRB1 agent and an anti-CD47/SIRPA agent (e.g., co-administration of an anti-MHC Class I/LILRB1 agent and an anti-CD47/SIRPA agent). Kits are also provided for practicing the methods of the disclosure.
Chlorella fractionated extracts containing high molecular weight Chlorella polysaccharide and polysaccharide complexes show immune modulatory, specifically immune stimulatory activity. The fractionated extracts are obtained by size fractionation of an extract of Chlorella and selecting fractions containing high molecular weight polysaccharides and polysaccharide complexes of about 1×10 4  Da to about 1×10 7  Da. A fraction of about 4×10 6  Da to about 1×10 7  Da is preferably obtained by size fractionation. The polysaccharide and polysaccharide complexes contain glucose and any combination of: galactose, rhamnose, mannose and arabinose, as well as N-acetyl glucosamine and N-acetyl galactosamine. The extracts may be treated with pronase, DNAse, RNAse and proteases to remove unassociated nucleic acids, ribonucleic acids and proteins. The extracts may also undergo treatment to effect cleavage of specific glycosidic linkages, the linkages being defined by their susceptibility to cleavage by amylase, amyloglucosidase, cellulase or neuraminidase. Chlorella extracts may be administered to a mammal to increase proliferation of splenocytes and increase production of cytokines such as IL-6, IL-10, INF-γ and TNF-α. They may be used as a supplement to a vaccination regimen.
BACKGROUND: In recent years, the escalating concern for neglected tropical diseases (NTDs) has been recognized as a pressing global health issue. This concern is acutely manifested in low- and middle-income countries, where there is an escalating prevalence among adolescents and young adults. The burgeoning of these conditions threatens to impair patients' occupational capabilities and overall life quality. Despite the considerable global impact of NTDs, comprehensive studies focusing on their impact in younger populations remain scarce. Our study aims to describe the global prevalence of neglected tropical diseases among people aged 15 to 39 years over the 30-year period from 1990 to 2019, and to project the disease burden of the disease up to 2040.
METHODS: Annual data on incident cases, mortality, and disability-adjusted life years (DALYs) for NTDs were procured from the Global Burden of Disease Study 2019 (GBD 2019). These data were stratified by global and regional distribution, country, social development index (SDI), age, and sex. We computed age-standardized rates (ASRs) and the numbers of incident cases, mortalities, and DALYs from 1990 to 2019. The estimated annual percentage change (EAPC) in the ASRs was calculated to evaluate evolving trends.
RESULTS: In 2019, it was estimated that there were approximately 552 million NTD cases globally (95% Uncertainty Interval [UI]: 519.9 million to 586.3 million), a 29% decrease since 1990. South Asia reported the highest NTD prevalence, with an estimated 171.7 million cases (95% UI: 150.4 million to 198.6 million). Among the five SDI categories, the prevalence of NTDs was highest in the moderate and low SDI regions in 1990 (approximately 270.5 million cases) and 2019 (approximately 176.5 million cases). Sub-Saharan Africa recorded the most significant decline in NTD cases over the past three decades. Overall, there was a significant inverse correlation between the disease burden of NTDs and SDI.
CONCLUSION: NTDs imposed over half a billion incident cases and 10.8 million DALYs lost globally in 2019-exerting an immense toll rivaling major infectious and non-communicable diseases. Encouraging declines in prevalence and disability burdens over the past three decades spotlight the potential to accelerate progress through evidence-based allocation of resources. Such strategic integration could substantially enhance public awareness about risk factors and available treatment options.
The present invention periodically and exhaustively extracts analysis dimension candidates from text data, such as medical literatures disclosed on the Internet. A name of disease, a medical agent, a checkup, and an operation included in actual clinical data are linked to the analysis dimension candidates. In the analysis dimension candidates, clinically important candidates and non-important candidates including extraction errors are mixed. To distinguish the candidates, weighting is provided to the link. First, a weight is made large when a level of an evidence of a medical literature from which an analysis dimension candidate is extracted is high. In literature groups of each name of disease, the degree of cooccurrence between a word of an analysis dimension candidate, and a word related to a medical agent/checkup/operation is calculated, and the weight of the link is made larger according to the magnitude of the degree of cooccurrence.
BACKGROUND Massive chylous leakage represents a rare yet potentially life-threatening complication following neck dissection, and its occurrence is even less common in the context of endoscopic thyroid surgery. Chylous leakage poses significant clinical management challenges, encompassing prolonged hospitalization, nutritional deficiencies, electrolyte imbalances, and the potential for infection. It is imperative for surgeons to remain vigilant and proactive in recognizing and managing chylous leakage to mitigate its potential impact on patient outcomes. CASE REPORT A 37-year-old woman presented with a thyroid nodule, and subsequent fine-needle aspiration biopsy confirmed the diagnosis of papillary thyroid carcinoma. She then underwent endoscopic thyroidectomy with central lymph node dissection via a bilateral areola approach and experienced significant postoperative chylous leakage. Various conservative management strategies were used to treat the leak, including fasting, parenteral nutrition, maintenance of electrolyte balance, and continuous infusion of somatostatin. After failure of a series of conservative treatments, the patient underwent a reoperation to address the leak via the initial approach. After identification of the leak site, the residual end of the lymphatic vessel was clamped with a biological clamp, and no further chylous leakage was observed. The drainage was removed 4 days after the second operation, and the patient was discharged on the fifth day. During follow-up, no abnormalities were observed. CONCLUSIONS Managing significant chylous leakage poses a challenge for surgeons. This complication is rare following endoscopic thyroidectomy with central lymph node dissection, and there remains a lack of experience in effective prevention and treatment. We aim to raise awareness through our case report.
MS CONTIN Tablets are a controlled-release oral formulation of morphine sulfate indicated for the management of moderate to severe pain when a continuous, around-the-clock analgesic is needed for an extended period of time. MS CONTIN does not release morphine continuously over the course of a dosing interval. The administration of single doses of MS CONTIN on a q12h dosing schedule will result in higher peak and lower trough plasma levels than those that occur when an identical daily dose of morphine is administered using conventional oral formulations on a q4h regimen. The clinical significance of greater fluctuations in morphine plasma level has not been systematically evaluated. (See DOSAGE AND ADMINISTRATION.)

Selection of patients for treatment with MS CONTIN® should be governed by the same principles that apply to the use of morphine or other potent opioid analgesics. Specifically, the increased risks associated with its use in the following populations should be considered: the elderly or debilitated and those with severe impairment of hepatic, pulmonary, or renal function; myxedema or hypothyroidism; adrenocortical insufficiency (e.g., Addison's Disease); CNS depression or coma; toxic psychosis; prostatic hypertrophy or urethral stricture; acute alcoholism; delirium tremens; kyphoscoliosis or inability to swallow.

The administration of morphine, like all opioid analgesics, may obscure the diagnosis or clinical course in patients with acute abdominal conditions.

Morphine may aggravate convulsions in patients with convulsive disorders, and all opioids may induce or aggravate seizures in some clinical settings.
Subjects in this arm will receive (1) donepezil and (2) cognitive remediation therapy (CRT). Subjects will take 5 mg/day of oral donepezil in the evening for the first 4 weeks, then 10 mg/day of oral donepezil in the evening until week 13.
In this study, an effective method for preparation of bioactive galloylated procyanidin B2-3'-O-gallate (B2-3'-G) was first developed by incomplete depolymerization of grape seed polymeric procyanidins (PPCs) using l-cysteine (Cys) in the presence of citric acid. The structure-activity relationship of B2-3'-G was further evaluated in vitro through establishing lipopolysaccharide (LPS)-induced inflammation in RAW264.7 cells. The results suggested that the better protective effects of B2-3'-G against inflammation were attributed to its polymerization degree and the introduction of the galloyl group, compared to its four corresponding structural units. In vivo experiments demonstrated that the B2-3'-G prototype was distributed in plasma, small intestine, liver, lung, and brain. Remarkably, B2-3'-G was able to penetrate the blood-brain barrier and appeared to play an important role in improving brain health. Furthermore, a total of 18 metabolites were identified in tissues. Potential metabolic pathways, including reduction, methylation, hydration, desaturation, glucuronide conjugation, and sulfation, were suggested.
FIELD: medical engineering. SUBSTANCE: method involves mixing starch, sugar and water in mass proportions of (10-40):(3-5):(56-87), respectively. Lactose is added to the produced mixture in mass proportions of 1:(2-3), respectively. The mixture is stirred until paste mass is achieved. Grains are formed under pressure of 3-5 kg/cm 2  through tubular canals with following drying at 60-80 C. Then, homeopathically diluted remedy is applied using preferential method involving filling cylindrical reservoir with medical drug for one third of the reservoir height. The reservoir is closed with filed cork having a member bearing a reservoir shaped like thimble preferentially manufactured from porcelain with perforated bottom filled with porous grains. The reservoir containing the grains is hold to some constant weight. EFFECT: high saturation degree when producing grained homeopathic remedy. 4 cl, 1 tbl